Nina Shah, MD | Authors

May 06, 2022

Nina Shah, MD, spoke about her key takeaways from a sub-analysis of the phase 2 KarMMa trial assessing correlates of complete response among those treated with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

May 04, 2022

Nina Shah, MD, spoke about analyzing correlates of complete response in patients with relapsed/refractory multiple myeloma who were treated with idecabtagene vicleucel.

April 25, 2022

At the 2022 Tandem Meetings, Nina Shah, MD, spoke about key findings from the phase 2 KarMMa trial that used idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

December 31, 2021

Nina Shah, MD, discusses the potential therapies that could emerge in 2022 for multiple myeloma.

December 30, 2021

Nina Shah, MD, looks to the future of treating patients with multiple myeloma.

December 29, 2021

Nina Shah, MD, discusses maintenance therapies in emerging clinical trials for multiple myeloma.

December 28, 2021

Nina Shah, MD, discusses some of the important phase 3 trials to emerge from the previous year in multiple myeloma.

December 27, 2021

Nina Shah, MD, touched on novel immunotherapies and other emerging therapies for patients with multiple myeloma.

December 26, 2021

Nina Shah, MD, details the process to choose optimal therapeutic options for patients with relapsed/refractory multiple myeloma.

December 25, 2021

Nina Shah, MD, on BCMA-directed treatments for patients with multiple myeloma.